Takeda presents data from Phase III TOURMALINE-MM1 study for NINLARO®

NINLARO® (ixazomib) is the first and only once-weekly oral proteasome inhibitor recently approved for multiple myeloma

Source: Pharmacy Europe - December 7, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick ash ixazomib Latest News multiple myeloma NINLARO proteasome inhibitor TOURMALINE-MM1 trial Source Type: news